Analyst firms · UBS · NVO

UBS NVO price target and rating history

Novo Nordisk A/S (NVO) · Health Care

UBS rates Novo Nordisk A/S (NVO) Neutral, as of its latest action on Aug 5, 2025. It has published 3 rating actions on NVO since June 2022, including 0 upgrades and 2 downgrades. Across 4 firms with a NVO price target in the last 12 months, the median target is $41.50.

Current rating

Neutral

Price target

Not stated

Median target, all firms

$41.50

Actions on NVO

3

Every UBS rating on NVO

• Aug 5, 2025
  DowngradeUBS downgrades to Neutral from Buy
• Jan 16, 2024
  ResumeUBS resumes coverage at Neutral
• Jun 28, 2022
  DowngradeUBS downgrades to Sell from Neutral

How other firms rate NVO

Each firm's latest rating and stated target in the last 12 months.

Questions about UBS and NVO

What is UBS's rating on NVO?

UBS rates NVO Neutral, a neutral rating, as of Aug 5, 2025.

When did UBS last change its view on NVO?

On Aug 5, 2025, UBS downgrades to Neutral from Buy.

How does UBS's NVO target compare with other analysts?

Across 4 firms with a NVO price target in the last 12 months, the median target is $41.50.

More NVO rating histories

• Morgan Stanley7
• Deutsche Bank4
• Bernstein4
• HSBC3

All UBS ratingsNVO news and filingsEvery analyst firm

From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.